GlassScriptPhysician profile
Ellen Brunetti
NPI 1902008238
$5,647.13
in general payments reported to CMS, 2019-2025
42 companies · $1,364 in 2025
The $1,364 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $766 · 2022: $791 · 2023: $1,517 · 2024: $1,210 · 2025: $1,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,001 · Education: $89.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,000.80 |
| Education | $89.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $665.07 | 2021-2025 | |
| Abbvie INC. | $640.66 | 2021-2025 | |
| Glaxosmithkline, LLC. | $566.81 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $548.73 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $478.37 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $340.48 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $303.30 | 2021-2025 | Xifaxan |
| Lilly USA, LLC | $288.13 | 2023-2025 | Zepbound, Mounjaro, Kisunla |
| Astellas Pharma US INC | $238.61 | 2021-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.53 | 2023-2025 | Jardiance, Ofev |
| Shield Therapeutics INC | $113.83 | 2025 | |
| Almatica Pharma LLC | $96.72 | 2021-2024 | Loreev Xr |
| Novartis Pharmaceuticals Corporation | $95.46 | 2022-2024 | |
| Lundbeck LLC | $93.94 | 2023-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $86.65 | 2022-2024 | Quviviq |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Brunetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.